Here's What Industry Insiders Say About Glioma Therapeutics Market

Posted by Loise Williams on October 17th, 2019

Glioma is a brain tumor that begins in the glial cells and spreads to the brain and spinal cord. There are low-grade and high-grade glioma types. The glioma treatment includes small molecules such as everolimus, carmustine, and temozolomide and biologics such as bevacizumab. 
As per the latest market research report published by Technavio, the global glioma therapeutics market size will grow by USD 861.69 million during 2019-2023. Get the free sample report below for the detailed information.

Download the free sample report @ http://bit.ly/2pohmgz

Currently, there are only seven gene therapies approved across the world, and these therapies have proved to be highly effective in the treatment of various indications. Thus, companies are conducting clinical trials for the treatment of glioma. 
These studies are still in the early phases of clinical trials. For instance, Tocagen is currently conducting a Phase II/III study on Toca 511, a novel gene therapy that consists of a purified retroviral replicating vector for encoding a modified yeast cytosine deaminase (CD) gene. 
Furthermore, Ad-RTS-hlL-12 is under development by Ziopharm Oncology and is in the Phase I stage of development for the treatment of glioma. Advances in regenerative medicine are expected to contribute significantly to the market. 
Hence, the development of gene therapy for the treatment of glioma is expected to be a key trend in the global glioma therapeutics market, which will grow at a CAGR of 9.34% during the forecast period. To know the complete and in-depth analysis and forecast of this market get the complete report by clicking the link below.